One of the most relevant brands among our more than 25 partners is TargetMol

<p>GB1908 is a selective oral inhibitor of galectin-1 (galectin-1), with Ki values of 57 nM for human galectin-1 and 72 nM for mouse galectin-1. It demonstrates over 50-fold selectivity for galectin-1 compared to galectin-3. GB1908 can be utilized in lung cancer research.</p>

Amlodipine besilate impurity D is a biochemical.

PD-L1/CD-73-IN-1 (compound CC-5) is an inhibitor of PD-L1 and CD73, with IC50 values of 6 nM and 0.773 μM, respectively. It effectively inhibits tumor cell growth both in vitro and in vivo.

Amlodipine besilate impurity E is a biochemical.

BDZ-P7 inhibits AMPA receptors GluA2, GluA1/2, GluA2/3, and GluA1 subunits with IC50 values of 3.03 μM, 3.14 μM, 3.19 μM, and 3.2 μM, respectively. It exhibits neuroprotective effects and is capable of restoring motor functions in mouse models of Parkinson’s disease.

<p>Amlodipine besilate impurity B is a biochemical.</p>

<p>RB-CO-PEG5-C2-CO-VH032 is a TRIM24 degrader that can inactivate the mTOR signaling pathway.</p>

5-Bromopentanoyl chloride serves as the PROTAC linker in PROTACATR degrader-2 and is utilized in the synthesis of PROTACs.

<p>JYQ-164 is a small molecule inhibitor targeting human Parkinson's disease protein 7 (PARK7/DJ-1). It functions by covalently and selectively targeting the critical residue Cys106 of PARK7, exhibiting an IC50 of 21 nM. JYQ-164 demonstrates five times greater inhibitory potency against PARK7 compared to the previously reported inhibitor, JYQ-88. It is applicable for research in Parkinson's disease and cancer.</p>

PSMA-trillium is a PSMA-targeting compound comprising a PSMA-targeting molecule (PSMA binding agent), a Macropa chelator, and a pharmacokinetics-modulating group (PK modulator). It acts as the non-radioactive variant of Actinium-225-PSMA-Trillium (BAY 3563254), boasting enhanced PSMA targeting and pharmacokinetic properties. PSMA-trillium can bind with Ac through either the Macropa chelator or the radioactive isotope Actinium-225. Actinium-225-PSMA-Trillium effectively inhibits metastatic castration-resistant prostate cancer (mCRPC).

RSV-IN-11 (compound 10b) exhibits antiviral activity against RSV, with an IC50 value of 4 μM. It is applicable for research on respiratory infections.

CYP51-IN-17 (compound 7a) is a potent CYP51 inhibitor with an IC50 of 0.377 μg/mL. It exhibits significant fungicidal activity against B. cinerea, with an EC50 of 0.326 μg/mL.

Antibiofilm agent-8 (compound Ru2) boosts antibacterial activity under visible light (400-700 nm, 10 J cm-2). It induces oxidative stress by promoting NADH oxidation and reactive oxygen species (ROS) generation, which disrupts the bacterial cell wall.

<p>Thalidomide-Pip-N-boc is a conjugate of an E3 ligase ligand and a linker. It is utilized in the synthesis of [PROTAC Degrader LLC0424].</p>

Dicycloplatin is an inducer of DNA damage. It activates doubly phosphorylated checkpoint kinase 2 (CHK2), breast cancer 1 (BRCA1), and triply phosphorylated p53 to induce DNA damage. Dicycloplatin can cause cell cycle arrest, inhibit proliferation, and trigger apoptosis in prostate cancer PC3 cells and lung cancer NCI/H446 cells. It is applicable for research in the field of cancer.

<p>The PKR Inhibitor, negative control, is an inactive structural analog of RNA-dependent protein kinase (PKR) inhibitors, serving as a negative control. Additionally, it can inhibit LK-induced neuronal death, demonstrating significant neuroprotective properties.</p>